Gene: PIGC
Official Full Name: phosphatidylinositol glycan anchor biosynthesis class Cprovided by HGNC
Gene Summary: This gene encodes an endoplasmic reticulum associated protein that is involved in glycosylphosphatidylinositol (GPI) lipid anchor biosynthesis. The GPI lipid anchor is a glycolipid found on many blood cells and serves to anchor proteins to the cell surface. The encoded protein is one subunit of the GPI N-acetylglucosaminyl (GlcNAc) transferase that transfers GlcNAc to phosphatidylinositol (PI) on the cytoplasmic side of the endoplasmic reticulum. Two alternatively spliced transcripts that encode the same protein have been found for this gene. A pseudogene on chromosome 11 has also been characterized. [provided by RefSeq, Jul 2008]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO36089 | PIGC Knockout cell line (HeLa) | Human | PIGC | 1:3~1:6 | Negative | Online Inquiry |
KO36090 | PIGC Knockout cell line (HCT 116) | Human | PIGC | 1:2~1:4 | Negative | Online Inquiry |
KO36091 | PIGC Knockout cell line (HEK293) | Human | PIGC | 1:3~1:6 | Negative | Online Inquiry |
KO36092 | PIGC Knockout cell line (A549) | Human | PIGC | 1:3~1:4 | Negative | Online Inquiry |
PIGC Gene Knockout Cell Lines are genetically engineered cell lines that have had the PIGC gene selectively inactivated, allowing researchers to study the resulting phenotypic changes and functional implications of PIGC deficiency. These cell lines serve as vital tools for investigating the biological roles of the PIGC gene, which is essential in glycosylation pathways and linked to various diseases, including congenital disorders of glycosylation.
The key mechanism underlying these knockout cell lines involves CRISPR/Cas9 technology, enabling precise gene editing that leads to a complete loss-of-function for the PIGC gene. This gene knockout facilitates a deeper understanding of how PIGC contributes to glycan synthesis and its implications in cellular processes. Researchers can utilize these cell lines to explore the molecular pathways impacted by PIGC deficiency, including cell signaling, adhesion, and overall cellular health.
The scientific importance of PIGC Gene Knockout Cell Lines cannot be overstated, as they provide critical insights into disease mechanisms, enable drug discovery, and facilitate the validation of therapeutic targets. In clinical settings, these models can aid in developing treatments for disorders involving glycosylation abnormalities, making them valuable for translational research.
Compared to traditional models, PIGC Gene Knockout Cell Lines offer significant advantages, including reproducibility, the ability to perform high-throughput screening, and specificity for the PIGC gene. This specificity establishes a controlled environment to unravel the multifaceted roles of glycosylation without the influence of other genetic factors, which often complicate study.
For researchers and clinicians focused on the evolving landscape of glycobiology and related diseases, PIGC Gene Knockout Cell Lines represent a powerful asset. They empower teams to gain actionable insights into the biology of glycosylation defects, paving the way for novel diagnostic and therapeutic innovations. Our company is dedicated to providing top-quality, rigorously validated biological products and models, supporting your research endeavors with scientific expertise and unwavering commitment to excellence.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.